This $518,661 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to advance the design of hemodialysis cartridges beyond the focus on urea removal. The project will test a novel parallel-plate dialyzer design that controls shear forces to potentially reduce platelet activation and clotting risks for the 548,000 Americans who rely on dialysis. The award to Vanderbilt...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a catheter end cap with an antimicrobial luminal insert to reduce the risk of bloodstream infections (BSI) in hemodialysis patients. The $591,844 award to Allvivo Vascular, Inc. supports the development and testing of the "Gatekeeper Antimicrobial Barrier Cap (GCAP)," a...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $499,890 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Pavaj Vascular Corporation to develop a novel therapy to prevent arteriovenous fistula (AVF) venous stenosis, a common complication in end-stage kidney disease patients requiring hemodialysis. The funding will support two main goals: 1) evaluating the stability and biocompatibility of a nanoparticle-based...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $704,672 to Flowpoint Medical Inc. to develop and evaluate an implantable self-sealing needle guide system to improve the safety and reliability of hemodialysis treatments. The key products/services being delivered through this Phase I SBIR project include: (1) refinement of the device's...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $2,095,816.00 to The DNA Medicine Institute, Inc. to develop a 5-minute point-of-care diagnostic test that can rapidly measure anti-Factor Xa activity and hemoglobin levels. This innovation aims to guide emergency management for patients on direct oral anticoagulants, enabling quicker delivery of life-saving interventions during...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) aims to develop a new class of biodegradable and elastic vascular grafts for hemodialysis access. The $298,371 award will fund the refinement of graft manufacturing techniques and testing of the grafts in a sheep model to mimic clinical hemodialysis practice. The project seeks to address the high...
This $1,165,276 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to investigate a novel biotherapeutic immunocytokine, F5111-IC, for suppressing inhibitor formation in hemophilia. The funding supports preclinical assessments to validate the targeted immunomodulatory technology in multiple animal models of hemophilia A and B. Key efforts include expressing and purifying the engineered fusion protein by The Johns Hopkins...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to advance the early detection and treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a serious condition following hematopoietic stem cell transplantation. The $143,968 award to Brigham & Women's Hospital Inc., a subsidiary of...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $595,464 Project Grant to Cerulean Scientific Inc. on September 25, 2024. The funding supports the development and commercialization of Cerulean Scientific's tethered liquid perfluorocarbon (TLP) coating technology for peripheral vascular grafts (PVGs). The key objectives are to evaluate the durability, anti-fouling properties, and thrombogenicity of...
This $256,000 National Science Foundation project grant supports the development of an automated chest tube to prevent clotting. Circulatech LLC will design and prototype a novel chest tube that proactively manages fluid flow within the catheter lumen to flush and drain the tube, reducing blood clot formation. Through a process called "dilutional coagulopathy," the tube will use sterile saline or anticoagulants to reduce thrombosis in the drainage space rather than relying on...